Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01877837 · ClinicalTrials.gov registry record · Phase 3
Stem Cell Transplantation for Sickle Cell Anemia
A Phase 3 study, sponsored by Hackensack Meridian Health.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT01877837 is a Phase 3 study that has completed, run by Hackensack Meridian Health. The registered enrollment target is 30 participants.
The verdict
NCT01877837, a Phase 3 study, has completed, sponsored by Hackensack Meridian Health.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
This protocol will be investigating the use of stem cell transplantation, in related donors, to cure sickle cell disease. Sickle cell disease is a recessive disorder caused by a point mutation that results in the substitution of valine for glutamic acid at the sixth position in the B-chain of hemoglobin. This leads to sickling of the red blood cells under many conditions, such as hypoxia, dehydration, and hyperthermia. The sickling leads to vaso-occlusion, which causes irreversible damage in almost all systems in the body, including the central nervous system (CNS), lungs, heart, bones, eyes, liver, and kidneys.
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- DRUG Alemtuzumab
- PROCEDURE Stem Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-06 |
| Est. Completion | 2021-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01877837
The ClinicalTrials.gov registry entry for NCT01877837 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fludarabine is the first listed.
NCT01877837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01877837 about?
NCT01877837 is a clinical study titled "Stem Cell Transplantation for Sickle Cell Anemia". This protocol will be investigating the use of stem cell transplantation, in related donors, to cure sickle cell disease. Sickle cell disease is a recessive disorder caused by a point mutation that results in the substitution of valine for glutamic acid at the sixth position in the B-chain of hemogl...
What is the current status of trial NCT01877837?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2011-06. Estimated completion is 2021-09.
What interventions are being tested in trial NCT01877837?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Alemtuzumab (DRUG), Stem Cells (PROCEDURE).
Who is sponsoring clinical trial NCT01877837?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.